Medicine and Dentistry
Acute Liver Failure
15%
Adolescent
10%
Alagille Syndrome
23%
Alanine Aminotransferase
12%
Alpha Tocopherol
8%
Antioxidant
9%
Antivirus Agent
8%
Ascites
9%
Biliary Atresia
100%
Bilirubin
25%
Biological Marker
9%
Biopsy
18%
Breathing
13%
Cholestasis
29%
Chronic Hepatitis B
43%
Chronic Hepatitis C
25%
Clinical Trial
9%
Cohort Effect
9%
Cystic Fibrosis
8%
Disease
41%
Fibrosis
15%
Health Care Cost
8%
Hepatitis B
25%
Hepatitis B Virus
34%
Hepatitis B(e) Antigen
23%
Hepatitis C
29%
Hepatitis C Virus
13%
Hepatocellular Carcinoma
18%
Hepatoportoenterostomy
32%
Infection
30%
Intrahepatic Cholestasis
8%
Lamivudine
8%
Liver Biopsy
23%
Liver Disease
51%
Liver Graft
38%
Liver Transplantation
58%
Neonatal Infant
10%
Pediatrics
91%
Pediatrics Patient
12%
Peginterferon
12%
Placebo
13%
Portal Hypertension
10%
Prevalence
11%
Primary Sclerosing Cholangitis
13%
Quality of Life
17%
Recurrent Disease
10%
Retinol
9%
Ribavirin
8%
Transplantation
20%
Virus Infection
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Liver Failure
18%
Adverse Event
15%
Alagille Syndrome
7%
Alanine Aminotransferase
16%
Alpha Tocopherol
10%
Alpha2a Interferon
10%
Antioxidant
9%
Antivirus Agent
13%
Bile Duct Atresia
16%
Bilirubin
8%
Biological Marker
9%
Chronic Hepatitis
8%
Chronic Hepatitis B
56%
Chronic Hepatitis C
51%
Clinical Trial
9%
Combination Therapy
7%
Cystic Fibrosis
7%
Disease
14%
Entecavir
10%
Fibrosis
10%
Hepatitis B
36%
Hepatitis B Antigen
8%
Hepatitis B Virus
43%
Hepatitis B(e) Antigen
33%
Hepatitis C
42%
Hepatitis C Virus
25%
Hepatitis C Virus Genotype 2
8%
Hepatitis C Virus Genotype 3
7%
Hepatitis E Virus
7%
Infection
46%
Interferon
21%
Lamivudine
15%
Liver Cell Carcinoma
16%
Liver Cirrhosis
16%
Liver Disease
29%
Monotherapy
9%
Oxidizing Agent
7%
Peginterferon
35%
Peginterferon Alpha
10%
Peginterferon Alpha2a
12%
Pharmacokinetics
15%
Placebo
20%
Primary Sclerosing Cholangitis
7%
Retinol
11%
Ribavirin
38%
Sofosbuvir
18%
Vancomycin
7%
Virus DNA
11%
Virus Hepatitis
9%
Virus Infection
12%
Keyphrases
Acute Liver Failure
11%
Biliary Atresia
48%
Canada
12%
Chronic Hepatitis B
46%
Chronic Hepatitis B Virus Infection
14%
Chronic Hepatitis C
32%
Chronic Hepatitis C Virus Infection
14%
Cirrhosis
15%
Clinical Trials
11%
Fibrosis
11%
Health-related Quality of Life
10%
Hepatitis B
32%
Hepatitis B e Antigen (HBeAg)
21%
Hepatitis B Surface Antigen (HBsAg)
13%
Hepatitis B Virus
29%
Hepatitis B Virus DNA
12%
Hepatitis B Virus Infection
9%
Hepatitis C
27%
Hepatitis C Virus
25%
Hepatitis C Virus Infection
22%
Hepatocellular Carcinoma
12%
Hepatoportoenterostomy
20%
Infections in children
14%
Interferon-α (IFN-α)
11%
Lamivudine
12%
Ledipasvir
11%
Liver
15%
Liver Biopsy
18%
Liver Disease
17%
Liver Transplant Recipients
10%
Liver Transplantation
19%
Natural History
9%
North America
19%
Pediatric
19%
Pediatric Liver Disease
13%
Pediatric Liver Transplant
14%
Pediatric Patients
12%
Pediatric Research
13%
Peginterferon
17%
Pegylated Interferon
19%
Placebo
10%
Primary Sclerosing Cholangitis
11%
Quality of Life
11%
Ribavirin
32%
Ropeginterferon alfa-2b
11%
Sofosbuvir
17%
Sustained Virological Response
11%
Total Bilirubin
10%
United States
19%
Virus
11%